Jaguar health announces launch of mytesi telehealth program

This innovative program connects patients who may be suffering from hiv-related diarrhea to a medical provider any day of the week and almost any hour of the day to determine if mytesi® is medically appropriate for them san francisco, ca / accesswire / may 11, 2022 / jaguar health, inc. (nasdaq:jagx) today announced that the company's telehealth program went live on may 6, 2022 for mytesi (crofelemer), jaguar's fda-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with hiv/aids on antiretroviral therapy (art). "telehealth facilitates faster and more expansive patient access to much needed medical care.
JAGX Ratings Summary
JAGX Quant Ranking